• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Prostate cancer: Reducing fracture risk in men on androgen deprivation therapy.

作者信息

Shahinian Vahakn B

出版信息

Nat Rev Urol. 2011 Jan;8(1):9-10. doi: 10.1038/nrurol.2010.210. Epub 2010 Dec 7.

DOI:10.1038/nrurol.2010.210
PMID:21135877
Abstract
摘要

相似文献

1
Prostate cancer: Reducing fracture risk in men on androgen deprivation therapy.前列腺癌：降低接受雄激素剥夺治疗男性的骨折风险
Nat Rev Urol. 2011 Jan;8(1):9-10. doi: 10.1038/nrurol.2010.210. Epub 2010 Dec 7.
2
Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.托瑞米芬降低接受雄激素剥夺治疗的前列腺癌男性骨折风险。
J Urol. 2010 Oct;184(4):1316-21. doi: 10.1016/j.juro.2010.06.022. Epub 2010 Aug 17.
3
Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.托瑞米芬降低接受雄激素剥夺治疗的前列腺癌男性骨折风险。
J Urol. 2013 Jan;189(1 Suppl):S45-50. doi: 10.1016/j.juro.2012.11.016.
4
Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy.托瑞米芬——一种预防前列腺癌及雄激素剥夺治疗并发症的有前景的疗法。
Expert Opin Investig Drugs. 2006 Mar;15(3):293-305. doi: 10.1517/13543784.15.3.293.
5
[Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer].[接受雄激素剥夺治疗的非转移性前列腺癌男性患者的骨质疏松症]
Wien Med Wochenschr. 2012 Sep;162(17-18):380-5. doi: 10.1007/s10354-012-0106-z. Epub 2012 Aug 9.
6
Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer.他莫昔芬可降低 80 岁以下接受雄激素剥夺治疗前列腺癌的男性的椎体骨折风险。
J Urol. 2011 Dec;186(6):2239-44. doi: 10.1016/j.juro.2011.07.090. Epub 2011 Oct 19.
7
Racial differences in bone mineral density and fractures in men receiving androgen deprivation therapy for prostate cancer.男性接受雄激素剥夺治疗前列腺癌时的骨矿物质密度和骨折的种族差异。
J Urol. 2012 Mar;187(3):889-93. doi: 10.1016/j.juro.2011.10.136. Epub 2012 Jan 15.
8
Re: Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. M. R. Smith, R. A. Morton, K. G. Barnette, P. R. Sieber, S. B. Malkowicz, D. Rodriguez, M. L. Hancock and M. S. Steiner. J Urol 2010;184:1316-1321.
J Urol. 2011 Jun;185(6):2430-1; author reply 2431-2. doi: 10.1016/j.juro.2011.02.036. Epub 2011 Apr 22.
9
Androgen deprivation therapy in prostate cancer: anticipated side-effects and their management.雄激素剥夺疗法治疗前列腺癌：预期的副作用及其处理。
Curr Opin Support Palliat Care. 2010 Sep;4(3):147-52. doi: 10.1097/SPC.0b013e32833bd913.
10
Factors associated with vertebral fractures in men treated with androgen deprivation therapy for prostate cancer.与接受雄激素剥夺疗法治疗前列腺癌的男性发生椎体骨折相关的因素。
J Urol. 2011 Aug;186(2):482-6. doi: 10.1016/j.juro.2011.03.111. Epub 2011 Jun 15.

引用本文的文献

1
Adoption of Intermittent Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study in American Urology Practice.晚期前列腺癌间歇性雄激素剥夺疗法的应用：一项基于美国泌尿外科实践的人群研究。
Urol Pract. 2015 Jul;2(4):190-198. doi: 10.1016/j.urpr.2014.11.001.
2
Type I Collagen Synthesis Marker Procollagen I N-Terminal Peptide (PINP) in Prostate Cancer Patients Undergoing Intermittent Androgen Suppression.Ⅰ型胶原合成标志物前胶原 I N 端肽（PINP）在接受间歇性雄激素抑制治疗的前列腺癌患者中的变化。
Cancers (Basel). 2011 Sep 15;3(3):3601-9. doi: 10.3390/cancers3033601.
3
Patterns of bone mineral density testing in men receiving androgen deprivation for prostate cancer.

本文引用的文献

1
Intermittent androgen suppression for prostate cancer.间歇性雄激素抑制治疗前列腺癌。
Nat Rev Urol. 2010 Oct;7(10):552-60. doi: 10.1038/nrurol.2010.141. Epub 2010 Sep 14.
2
Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.托瑞米芬降低接受雄激素剥夺治疗的前列腺癌男性骨折风险。
J Urol. 2010 Oct;184(4):1316-21. doi: 10.1016/j.juro.2010.06.022. Epub 2010 Aug 17.
3
Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States.
男性前列腺癌去势治疗后骨密度检测模式。
J Gen Intern Med. 2013 Nov;28(11):1440-6. doi: 10.1007/s11606-013-2477-2. Epub 2013 May 14.
雄激素剥夺疗法在美前列腺癌男性中的普遍使用和新发病例。
Urol Oncol. 2011 Nov-Dec;29(6):647-53. doi: 10.1016/j.urolonc.2009.09.004. Epub 2009 Nov 19.
4
Denosumab in men receiving androgen-deprivation therapy for prostate cancer.地诺单抗用于接受雄激素剥夺治疗的前列腺癌男性患者。
N Engl J Med. 2009 Aug 20;361(8):745-55. doi: 10.1056/NEJMoa0809003. Epub 2009 Aug 11.
5
Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial.每周一次口服阿仑膦酸钠对接受前列腺癌雄激素剥夺治疗男性骨质流失的影响：一项随机试验。
Ann Intern Med. 2007 Mar 20;146(6):416-24. doi: 10.7326/0003-4819-146-6-200703200-00006.
6
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.前列腺癌雄激素剥夺治疗期间的糖尿病和心血管疾病
J Clin Oncol. 2006 Sep 20;24(27):4448-56. doi: 10.1200/JCO.2006.06.2497.
7
Risk of fracture after androgen deprivation for prostate cancer.前列腺癌雄激素剥夺治疗后的骨折风险。
N Engl J Med. 2005 Jan 13;352(2):154-64. doi: 10.1056/NEJMoa041943.
8
Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation.雷洛昔芬的安全性及不良反应：雷洛昔芬评估的多项结果
Obstet Gynecol. 2004 Oct;104(4):837-44. doi: 10.1097/01.AOG.0000137349.79204.b8.
9
Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.唑来膦酸预防非转移性前列腺癌雄激素剥夺治疗男性骨质流失的随机对照试验。
J Urol. 2003 Jun;169(6):2008-12. doi: 10.1097/01.ju.0000063820.94994.95.